It turns out that Mithril Medicine, the AI healthcare company acquired by Anthropic, is a very typical "one-man company," with founder Cody Tranbarger being the only full-time employee. Mithril Medicine has no labs, no R&D team, and not even a traditional office. At its core, it's the founder himself, a group of external consultants, and over ten contract labs, pushing drug development all the way to the mouse testing stage. A quick look at founder Cody's background reveals it's not exactly a traditional scientist's path. He studied biology and economics at Amherst College, and later earned an MS/MBA in biotechnology from Harvard. His career began at Goldman Sachs' healthcare investment banking, then moved to Casdin Capital for gene therapy investments, then to Prime Medicine for business development, and later to Atlas Ventures for an entrepreneur-in-residence position, while also founding another gene-writing company, Revision Bio. He also served on the board of Cure Rare Disease for a long time, maintaining a long-standing interest in rare diseases and personalized medicine. These experiences have given him the expertise to assess the viability of a project and to navigate relationships with labs, CROs, and investors. Mithril's approach is straightforward: they don't maintain their own wet labs, outsourcing antibody production, cell experiments, and mouse research entirely to external organizations. Cody is solely responsible for setting the direction, making decisions, monitoring progress, and revising plans. Claude handles the numerous daily contract communications, data processing, experimental plan adjustments, and email exchanges. The company calls this model "Pipeline-in-a-Person"—one person carries the entire pipeline forward, judgment remains with the person, and execution is largely delegated to tools and external partners. The project itself targets two rare childhood muscular dystrophys, primarily using bispecific antibodies to attempt to "bridge" residual proteins and muscle fibers in the muscle. From project initiation to obtaining relatively positive results in mice, it took less than 18 months. The mouse experiments were small-scale, and the methodologies had limitations (not fully randomized, inconsistent testing times, etc.), and the technical report has not yet undergone peer review, but it at least proves that this minimalist team combined with external collaboration is viable in the early exploratory stages. In July of this year, Anthropic acquired Mithril Medicine. For Anthropic, this acquisition provided both a specific drug project and a real-world case study: how one person can use AI to manage the coordination and daily operations of multiple laboratories to a manageable level. Essentially, Mithril didn't start with a technology platform or a large team; rather, it built its success on the founder's judgment, industry experience, and willingness to outsource a significant amount of execution work to tools, taking a pharmaceutical company from scratch to the stage with mouse data. This model is uncommon in the biopharmaceutical field, but it is precisely because of its extreme nature that it became one of the reasons for its acquisition.